First Light Asset Management LLC Sells 134,948 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

First Light Asset Management LLC trimmed its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,805,184 shares of the company’s stock after selling 134,948 shares during the period. Centessa Pharmaceuticals makes up approximately 9.2% of First Light Asset Management LLC’s investment portfolio, making the stock its 2nd largest holding. First Light Asset Management LLC owned 4.40% of Centessa Pharmaceuticals worth $97,237,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of CNTA. State Street Corp acquired a new stake in Centessa Pharmaceuticals during the third quarter valued at approximately $777,000. Geode Capital Management LLC lifted its stake in Centessa Pharmaceuticals by 68.7% during the third quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock valued at $905,000 after purchasing an additional 23,058 shares during the last quarter. Franklin Resources Inc. lifted its stake in Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after purchasing an additional 1,145,823 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in Centessa Pharmaceuticals during the third quarter valued at approximately $4,305,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Centessa Pharmaceuticals by 1,969.2% during the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company’s stock valued at $2,173,000 after acquiring an additional 129,335 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now directly owns 225,007 shares of the company’s stock, valued at $3,863,370.19. This represents a 3.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Karen M. Anderson sold 6,471 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $109,101.06. Following the completion of the sale, the insider now directly owns 54,322 shares of the company’s stock, valued at approximately $915,868.92. This trade represents a 10.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 213,824 shares of company stock valued at $3,497,018 in the last ninety days. Company insiders own 11.59% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CNTA. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim restated a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Piper Sandler began coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They set an “overweight” rating and a $38.00 price target on the stock. Finally, Morgan Stanley restated an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $27.71.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $13.79 on Monday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a fifty day simple moving average of $14.42 and a 200 day simple moving average of $15.87. The company has a market cap of $1.84 billion, a P/E ratio of -9.01 and a beta of 1.53. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. On average, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.